Market Closed -
Hong Kong S.E.
01:38:16 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.37
HKD
|
+9.60%
|
|
+39.80%
|
-39.91%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
19,309
|
4,733
|
925.7
|
925.7
|
-
|
Enterprise Value (EV)
1 |
16,477
|
3,555
|
1,025
|
-30.53
|
-306
|
P/E ratio
|
-2.83
x
|
-9.71
x
|
-8.63
x
|
-1.95
x
|
-2.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
32.2
x
|
3.63
x
|
-
|
5.12
x
|
EV / Revenue
|
-
|
24.2
x
|
2.46
x
|
-
|
-1.69
x
|
EV / EBITDA
|
-3.95
x
|
-6.27
x
|
-1.75
x
|
0.04
x
|
0.5
x
|
EV / FCF
|
-1,61,02,317
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
5.78
x
|
1.48
x
|
0.49
x
|
0.44
x
|
0.58
x
|
Nbr of stocks (in thousands)
|
7,20,292
|
7,27,203
|
7,29,638
|
7,29,638
|
-
|
Reference price
2 |
26.81
|
6.509
|
1.269
|
1.269
|
1.269
|
Announcement Date
|
22/03/22
|
24/03/23
|
22/03/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
147.2
|
416.7
|
-
|
180.7
|
EBITDA
1 |
-
|
-4,176
|
-567.5
|
-584.3
|
-735.9
|
-615.8
|
EBIT
1 |
-
|
-703
|
-584.5
|
-600
|
-750.1
|
-629
|
Operating Margin
|
-
|
-
|
-397.09%
|
-143.97%
|
-
|
-348.07%
|
Earnings before Tax (EBT)
1 |
-
|
-4,191
|
-489.8
|
-184.4
|
-644.4
|
-527.7
|
Net income
1 |
-1,190
|
-4,164
|
-484.3
|
-174.8
|
-527.6
|
-460.5
|
Net margin
|
-
|
-
|
-329.03%
|
-41.95%
|
-
|
-254.86%
|
EPS
2 |
-6.220
|
-9.480
|
-0.6700
|
-0.2400
|
-0.6500
|
-0.5300
|
Free Cash Flow
|
-
|
-1,023
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/06/21
|
22/03/22
|
24/03/23
|
22/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 S2
|
---|
Net sales
1 |
22.83
|
4.193
|
143
|
63.15
|
-
|
-
|
353.6
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-347.6
|
-136.7
|
-189.9
|
-370.5
|
-391.6
|
15.09
|
-121
|
-125.3
|
-246.3
|
-134.6
|
-281.3
|
Net margin
|
-
|
-8,289.7%
|
-95.61%
|
-300.72%
|
-
|
-
|
4.27%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.4800
|
-0.1900
|
-0.2600
|
-0.5100
|
-0.5300
|
0.0200
|
-0.1700
|
-0.1700
|
-0.3400
|
-0.1800
|
-0.3200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/09/22
|
23/08/22
|
24/03/23
|
22/08/23
|
-
|
-
|
22/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
2,832
|
1,178
|
486
|
956
|
1,232
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-1,023
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-519%
|
-14.8%
|
-5.54%
|
-25.9%
|
-27.7%
|
ROA (Net income/ Total Assets)
|
-
|
-171%
|
-13.8%
|
-
|
-
|
-
|
Assets
1 |
-
|
2,440
|
3,502
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
4.640
|
4.390
|
4.220
|
2.900
|
2.200
|
Cash Flow per Share
|
-
|
-2.000
|
-
|
-
|
-
|
-
|
Capex
|
-
|
1.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/06/21
|
22/03/22
|
24/03/23
|
22/03/24
|
-
|
-
|
Last Close Price
1.269
CNY Average target price
4.303
CNY Spread / Average Target +239.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -39.91% | 117M | | -1.46% | 104B | | +6.71% | 97.47B | | +5.71% | 22.25B | | -12.63% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.28% | 16.36B | | +7.48% | 14.39B | | +37.53% | 12.37B |
Bio Therapeutic Drugs
|